预测成人原发性脑肿瘤患者脑照射后神经认知功能下降风险
本研究纳入2019至2022年接受根治性光子放疗和/或质子放疗的219例原发性脑肿瘤成人患者,构建并内部测试预测6个月、1年及2年神经认知功能下降的正常组织并发症概率模型。6个月、1年、2年神经认知功能下降发生率分别为50%、44.5%、42.7%,联合模型在6个月时预测效能最佳(AUC=0.79,MAE=0.021)。
要点
- 6个月、1年、2年神经认知功能下降发生率分别为50%、44.5%、42.7%。
- 6个月联合模型纳入放疗年龄>56岁(OR=5.71)、超重(OR=0.49)、肥胖(OR=0.35)、化疗(OR=2.23)等预测因子。
- 联合模型在6个月、1年、2年时间点的AUC分别为0.79、0.72、0.69。
核心结论
- 所提出的正常组织并发症概率模型使用易于获取的预测因子识别脑放疗后神经认知功能下降高风险患者。
- 这些模型可能为放疗相关决策及治疗后神经认知康复干预提供基础。
研究设计与样本
- 纳入219例2019至2022年接受根治性光子放疗和/或质子放疗的原发性脑肿瘤成人患者。
- 使用受控口头词语联想测试、霍普金斯词语学习测试修订版和连线测验客观测量神经认知功能下降。
- 对多个脑结构的临床和剂量体积参数进行统计建模,构建临床模型、剂量体积模型及联合模型并进行内部测试,评估判别能力(AUC)、校准(MAE)和净获益。
主要发现
- 6个月、1年、2年神经认知功能下降发生率分别为50%、44.5%、42.7%。
- 6个月神经认知功能下降联合模型纳入以下预测因子:放疗时年龄>56岁(OR=5.71)、超重(OR=0.49)、肥胖(OR=0.35)、化疗(OR=2.23)、脑V20 Gy≥20%(OR=3.53)、脑干体积≥26 cc(OR=0.39)、下丘脑体积≥0.5 cc(OR=0.4)。
- 决策曲线分析显示联合模型在6个月(AUC=0.79,MAE=0.021)、1年(AUC=0.72,MAE=0.027)、2年(AUC=0.69,MAE=0.038)时间点具有最高净获益。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Deterioration of neurocognitive function in adult patients with a primary brain tumor is the most concerning side effect of radiotherapy. This study aimed to develop and evaluate normal-tissue complication probability (NTCP) models using clinical and dose-volume measures for 6-month, 1-year, and 2-year Neurocognitive Decline (ND) postradiotherapy. METHODS: A total of 219 patients with a primary brain tumor treated with radical photon and/or proton radiotherapy (RT) between 2019 and 2022 were included. Controlled oral word association test, Hopkins verbal learning test-revised, and trail making test were used to objectively measure ND. A comprehensive set of potential clinical and dose-volume measures on several brain structures were considered for statistical modeling. Clinical, dose-volume and combined models were constructed and internally tested in terms of discrimination (area under the curve, AUC), calibration (mean absolute error, MAE), and net benefit. RESULTS: Fifty percent, 44.5%, and 42.7% of the patients developed ND at 6-month, 1-year, and 2-year time points, respectively. The following predictors were included in the combined model for 6-month ND: age at radiotherapy > 56 years (OR = 5.71), overweight (OR = 0.49), obesity (OR = 0.35), chemotherapy (OR = 2.23), brain V20 Gy ≥ 20% (OR = 3.53), brainstem volume ≥ 26 cc (OR = 0.39), and hypothalamus volume ≥ 0.5 cc (OR = 0.4). Decision curve analysis showed that the combined models had the highest net benefits at 6-month (AUC = 0.79, MAE = 0.021), 1-year (AUC = 0.72, MAE = 0.027), and 2-year (AUC = 0.69, MAE = 0.038) time points. CONCLUSIONS: The proposed NTCP models use easy-to-obtain predictors to identify patients at high risk of ND after brain RT. These models can potentially provide a base for RT-related decisions and post-therapy neurocognitive rehabilitation interventions.
引用
- Tohidinezhad F, Zegers CML, Vaassen F, et al. Predicting the risk of neurocognitive decline after brain irradiation in adult patients with a primary brain tumor. Neuro Oncol. 2024. PMID: 38595122. doi:10.1093/neuonc/noae035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。